Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Navitoclax in HGSC and TNBC
NCT05358639Phase 1Active, not recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Nov 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navitoclax in High-Grade Serous Ovarian Carcinoma (HGSOC) and triple negative breast cancer (TNBC), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Recommended Phase II Dose at 2 years. Started Nov 2022; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05358639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358639.